SNOA

Sonoma Pharmaceu

• TipRanks·10/06 21:01

  Sonoma Pharmaceuticals Adopts New Tax-Protection Rights Plan

• TipRanks·09/17 10:32

  Sonoma Pharmaceuticals Announces Results of Annual Shareholder Meeting

• TipRanks·08/19 21:48

  Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting

• Seeking Alpha·08/06 13:07

  Sonoma Pharmaceuticals GAAP EPS of -$0.09, revenue of $6.41M

• Benzinga·08/06 12:34

  Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoY

• Benzinga·08/06 12:33

  Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

• TipRanks·06/30 13:05

  Sonoma Pharmaceuticals receives 510(k) clearance for Microdacyn solution

• Benzinga·06/30 13:03

  Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation Solution

• NASDAQ·06/26 16:04

  Jade Biosciences Appoints Mark Eisner To The Board Of Directors

• TipRanks·06/18 22:41

  Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity

• Benzinga·06/18 20:36

  Sonoma Pharmaceuticals Increases Maximum Aggregate Offering Price Of Common Stock To $3.64M

• Seeking Alpha·06/16 20:24

  Sonoma Pharmaceuticals GAAP EPS of -$0.33, revenue of $5.56M

• Benzinga·06/16 20:17

  Sonoma Pharmaceuticals Q4 EPS $(0.33) Misses $(0.24) Estimate, Sales $5.561M Miss $5.565M Estimate

• TipRanks·04/30 22:55

  Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital

• Benzinga·04/30 21:36

  Sonoma Pharmaceuticals Enters Underwriting Agreement With Dawson James Securities On April 24, 2026; To Issue 2,962,962 Units At $1.35 Per Unit In Public Offering